Changing the treatment of permanent neonatal diabetes mellitus from insulin to glibenclamide in a 4-month-old infant with KCNJ11 activating mutation

International Journal of Preventive Medicine

Volumn 4, Issue 9, 2013, Pages 1078-1081

  Ilkhanipoor, Homa ^a   Karamizadeh, Zohreh ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

KCNJ11; Permanent neonatal diabetes mellitus; Sulfonylurea

Indexed keywords

BICARBONATE; GLIBENCLAMIDE; GLUCOSE; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; ISOPHANE INSULIN; POTASSIUM; SODIUM;

ARTICLE; CASE REPORT; DIABETIC KETOACIDOSIS; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EVENING DOSAGE; FEEDING DIFFICULTY; GENE MUTATION; GENETIC SCREENING; GENETIC VARIABILITY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HETEROZYGOTE; HUMAN; HYPERGLYCEMIA; INFANT; INSULIN TREATMENT; KCNJ11 GENE; MALE; METABOLIC ACIDOSIS; MORNING DOSAGE; MUTATIONAL ANALYSIS; NEWBORN DIABETES MELLITUS; PERMANENT NEONATAL DIABETES MELLITUS; PH; RESTLESSNESS; SODIUM BLOOD LEVEL; TACHYPNEA; UREA NITROGEN BLOOD LEVEL;

EID: 84883867056     PISSN: 20087802     EISSN: 20088213     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Nieves-Rivera F, González-Pijem L. Neonatal diabetes mellitus: Description of two Puerto Rican children with KCNJ11 activating gene mutation. PR Health Sci J 2011;30:87-9.
2. Greeley SA, John PM, Winn AN, Ornelas J, Lipton RB, Philipson LH, et al. The cost-effectiveness of personalized genetic medicine: The case of genetic testing in neonatal diabetes. Diabetes Care 2011;34:622-7.
3. Gloyn AL, Cummings EA, Edghill EL, Harries LW, Scott R, Costa T, et al. Permanent neonatal diabetes due to paternal germline mosaicism for an activating mutation of the KCNJ11 Gene encoding the Kir6.2 subunit of the beta-cell potassium adenosine triphosphate channel. J Clin Endocrinol Metab 2004;89:3932-5.
4. Ashcroft FM. New uses for old drugs: Neonatal diabetes and sulphonylureas. Cell Metab 2010;11:179-81.
5. Støy J, Greeley SA, Paz VP, Ye H, Pastore AN, Skowron KB, et al. Diagnosis and treatment of neonatal diabetes: A United States experience. Pediatr Diabetes 2008;9:450-9.
6. Dupont J, Pereira C, Medeira A, Duarte R, Ellard S, Sampaio L. Permanent neonatal diabetes mellitus due to KCNJ11 mutation in a Portuguese family: Transition from insulin to oral sulfonylureas. J Pediatr Endocrinol Metab 2012;25:367-70.
7. Siklar Z, Ellard S, Okulu E, Berberoǧlu M, Young E, Savaş Erdeve S, et al. Transient neonatal diabetes with two novel mutations in the KCNJ11 gene and response to sulfonylurea treatment in a preterm infant. J Pediatr Endocrinol Metab 2011;24:1077-80.
8. Al-Mahdi M, Al Mutair A, Al Balwi M, Hussain K. Successful transfer from insulin to oral sulfonylurea in a 3-year-old girl with a mutation in the KCNJ11 gene. Ann Saudi Med 2010;30:162-4.
9. Wambach JA, Marshall BA, Koster JC, White NH, Nichols CG. Successful sulfonylurea treatment of an insulin-naïve neonate with diabetes mellitus due to a KCNJ11 mutation. Pediatr Diabetes 2010;11:286-8.
10. Ting WH, Huang CY, Lo FS, Lee HC, Lin CL, Guo WL, et al. Improved diabetic control during oral sulfonylurea treatment in two children with permanent neonatal diabetes mellitus. J Pediatr Endocrinol Metab 2009;22:661-7.
11. Kim MS, Kim SY, Kim GH, Yoo HW, Lee DW, Lee DY. Sulfonylurea therapy in two Korean patients with insulin-treated neonatal diabetes due to heterozygous mutations of the KCNJ11 gene encoding Kir6.2. J Korean Med Sci 2007;22:616-20.
12. Chan YM, Laffel LM. Transition from insulin to glyburide in a 4-month-old girl with neonatal diabetes mellitus caused by a mutation in KCNJ11. Pediatr Diabetes 2007;8:235-8.
13. Shah B, Breidbart E, Pawelczak M, Lam L, Kessler M, Franklin B. Improved long-term glucose control in neonatal diabetes mellitus after early sulfonylurea allergy. J Pediatr Endocrinol Metab 2012;25:353-6.
14. Vaxillaire M, Populaire C, Busiah K, Cavé H, Gloyn AL, Hattersley AT, et al. Kir6.2 mutations are a common cause of permanent neonatal diabetes in a large cohort of French patients. Diabetes 2004;53:2719-22.
15. Sagen JV, Raeder H, Hathout E, Shehadeh N, Gudmundsson K, Baevre H, et al. Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: Patient characteristics and initial response to sulfonylurea therapy. Diabetes 2004;53:2713-8.
16. Klupa T, Skupien J, Mirkiewicz-Sieradzka B, Gach A, Noczynska A, Zubkiewicz-Kucharska A, et al. Efficacy and safety of sulfonylurea use in permanent neonatal diabetes due to KCNJ11 gene mutations: 34-month median follow-up. Diabetes Technol Ther 2010;12:387-91.
17. Vendramini MF, Gurgel LC, Moisés RS. Long-term response to sulfonylurea in a patient with diabetes due to mutation in the KCNJ11 gene. Arq Bras Endocrinol Metabol 2010;54:682-4.